男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / The 4th China Intl Import Expo

Sanofi accelerates digital innovation to meet health needs of Chinese people

chinadaily.com.cn | Updated: 2021-11-06 06:40
Share
Share - WeChat
Sanofi's booth at the fourth CIIE in Shanghai. [Photo provided to chinadaily.com.cn]

In an era of "internet + healthcare," French pharmaceutical company Sanofi is putting digital innovation at the core of development strategies, in a bid to bring more innovative solutions to meet the diverse health needs of Chinese people, a company's top executive said.

By accelerating drug innovation and improving the quality and efficiency of disease diagnosis and treatment, Sanofi has been improving access to healthcare, helping to meet the most pressing medical needs that China is facing in the coming decade, Pius S. Hornstein, country lead of Sanofi Greater China, said.

"We've noticed accelerated innovation in China's healthcare system," Hornstein said. As an innovator in digital healthcare, the Paris-headquartered company has been dedicated to promoting digital transformation of the healthcare industry.

As early as in 2019, Sanofi China took a step ahead of the industry to establish a dedicated team for internet hospitals, becoming a pioneer of internet healthcare among multinational pharmaceutical companies.

This year, the Sanofi internet hospital team will make its debut at the fourth China International Import Expo scheduled from Nov 5 to 10 in Shanghai, focusing on the team's innovations guided by its digitalization strategy.

Sanofi has attended the previous three editions of the CIIE, the world's first import-themed national-level exhibition.

Based on the concept of "Innovation Accelerator", Sanofi's booth aims at demonstrating the company's commitment and investment in China, showcasing diverse healthcare solutions and channels, and highlighting the successful results of its digital innovations.

A total of 20 star products, including Sarclisa, for treatment of relapsed multiple myeloma, and Coplavix, for the prevention of atherosclerotic thrombosis in adult patients with acute coronary syndrome who have taken clopidogrel and aspirin, and three other consumer health products will be displayed for the first time.

A Sanofi's production base in Beijing. [Photo provided to chinadaily.com.cn]

Sanofi is also working with leading internet companies and startups, in an effort to create a new era of digital healthcare as a leading provider of digital solutions, Hornstein said.

In September, 2020, Sanofi, together with JD Health, a digital healthcare platform under JD, launched an online center for the diagnosis and treatment of diabetes, the first health management platform for Chinese patients with diabetes, which ushers in a new era of one-stop health management service.

In June, Sanofi joined hands with JD Heath again, announcing a strategic partnership to leverage their strengths to promote strategic initiatives in five areas-prescription drugs, vaccines, consumer health products, medical services, and commercial insurance.

Among the first batch of foreign companies to come to China after the beginning of China's reform and opening-up, Sanofi entered the Chinese market in 1982 and has seen sustained rapid development in the country.

In the nearly 40 years, Sanofi has brought to China more than 40 products spanning the areas of chronic disease, specialty drugs, vaccines, and consumer health.

Sanofi has also established three manufacturing sites, four research and development centers, and one digital innovation center in China. In particular, the Beijing Production Base, which was completed 25 years ago, has now become Sanofi's largest manufacturing site for insulin in the Asia-Pacific, supplying high-quality products to China as well as other Asia-Pacific markets, including South Korea, Japan, and Australia.

"We hope that the spirit of innovation that Sanofi is actively promoting will help the sustainable development of the healthcare ecosystem, and contributes to the goals of the 14th Five Year Plan and the Healthy China 2030 initiative", Hornstein said.

"In the future, we will accelerate the introduction of innovative products, to introduce more than 25 innovative medicines and vaccines to China between 2020 and 2025 to meet diverse health needs."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 潜江市| 普安县| 南投市| 柞水县| 剑河县| 宜兰县| 银川市| 星座| 桦川县| 师宗县| 长治市| 新郑市| 县级市| 阿图什市| 稷山县| 克山县| 依兰县| 忻州市| 武山县| 和平区| 凤城市| 达拉特旗| 克山县| 榆中县| 京山县| 霍山县| 海兴县| 惠水县| 贵溪市| 定襄县| 治多县| 吉隆县| 新邵县| 微山县| 乌拉特前旗| 竹山县| 辽中县| 大埔县| 嘉荫县| 镇康县| 嘉祥县|